The significance of in vitro changes in immune function accompanying exercise training is unclear. To determine the effect of exercise on the response of the intact immune system to a challenge in vivo, we measured the speed and overall immunoglobulin G (IgG) response to influenza vaccination in humans engaged in different intensities of activity. Male participants (n = 21) were split into heavy and light training groups. Venous blood samples were collected 0, 2, 4, 7, 10 and 14 days after vaccination with trivalent influenza vaccine, and also 12 months after initial vaccination. Serum IgG was determined by enzyme-linked immunosorbant assay. There was a significant difference in baseline IgG between groups, but no difference in IgG concentration 14 days after vaccination. The IgG concentration remained elevated 12 months post-vaccination in the heavy training group. The results suggest a positive relationship between habitual physical activity and baseline antibody concentrations, which, in turn, affects the relative magnitude (fold or percentage increase) of the antibody response to vaccination. The training loads of the participants in this study had no effect on overall IgG measured 14 days after vaccination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/0264041031000140464 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix Vaccine When Given to Healthy Infants at 3 and 12 Months of Age.
Infect Dis Ther
January 2025
Vaccine Research and Development, Pfizer R&D UK Ltd, Marlow, UK.
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) in infants were evaluated.
Methods: In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series).
Effects of educational interventions for community pharmacists on promoting human papillomavirus vaccination: A randomized double-blind parallel group comparison trial.
Vaccine X
January 2025
Shinagawa Pharmaceutical Association, 2-4-2 Nakanobu, Shinagawa-ku, Tokyo 142-0053, Japan.
Objective: Owing to persistent concerns about side effects, human papillomavirus (HPV) vaccination rates in Japan have remained low. Pharmacists are therefore encouraged to improve vaccination rates by providing accurate information. This study evaluated the impact of educational interventions on pharmacists' knowledge and willingness to recommend the HPV vaccine.
View Article and Find Full Text PDFUnderstanding the local-level variations in seasonality of human respiratory syncytial virus infection: a systematic analysis.
BMC Med
January 2025
Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China.
Background: While previous reports characterised global and regional variations in RSV seasonality, less is known about local variations in RSV seasonal characteristics. This study aimed to understand the local-level variations in RSV seasonality and to explore the role of geographical, meteorological, and socio-demographic factors in explaining these variations.
Methods: We conducted a systematic literature review to identify published studies reporting data on local-level RSV season onset, offset, or duration for at least two local sites.
Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses.
J Infect Public Health
January 2025
Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. Electronic address:
Background: Given the limited available data about to the number of vaccine doses administered over an extended time in Iran, the immune status of vaccinated individuals and any potential disparities in this regard among those who received different numbers of vaccine doses remain unknown. Therefore, this study aimed to assess humoral immunity of individuals who received different doses of the COVID-19 vaccines in Iran.
Methods: This study was conducted from February, 2022 to December 2023 including 605 vaccinated subjects.
Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
Vaccine
January 2025
Medical Technology Innovation Center, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address:
This study was conducted at 112 government and Juntendo University hospitals in February 2021 for the primary series of SARS-CoV-2 vaccinations. We compared the timing of solicited adverse event (AE) onset and prevalence of unsolicited AEs for Pfizer, Moderna, and AstraZeneca vaccines in a nationwide, large-scale prospective cohort study. The Pfizer and Moderna mRNA vaccines were associated with a higher frequency of fever after the second dose than after the first dose.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!